Regenerative Medical Technology Group net loss widens to US$ 2.91 million in Q2 FY26; revenue rises to US$ 4.02 million
Reuters2026/08/19 21:33- Regenerative Medical Technology Group posted Q2 revenue of US$ 4.02 million, up 309.02% year over year; net loss widened to US$ 2.91 million.
- Operating income swung to US$ 565,977 from an operating loss; interest expense climbed to US$ 2.23 million, lifting total other expense.
- For the six months, revenue rose 183.75% to US$ 6.66 million; net loss widened to US$ 3.22 million.
- Cash and cash equivalents increased 38.32% to US$ 1.32 million at June 30, 2026; operating cash flow was US$ 434,098.
- Business updates included launches of the ISSCA Mobile App on June 17, 2026, and the ISSCA AI Clinical Intelligence Platform on June 23, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Breakthrough in US-Canada trade negotiations: Reports indicate the US plans to halve steel and aluminum tariffs to 25% and reduce automobile tariffs to 15%
According to media reports, the United States and Canada have reached a preliminary framework for a trade agreement, under which tariffs on certain Canadian steel and aluminum products exported to the U.S. will be reduced from the current 50% to 25%, and the tariff on Canadian automobile exports will be lowered from 25% to 15%. The news caused a surge in Canadian steel companies and a sharp drop in U.S. steel companies. Agreement details have yet to be finalized, U.S. manufacturing groups are putting pressure on, and with Trump's unpredictability, uncertainty remains until Friday's deadline.
HIVE director Dave Perrill sells 100,000 common shares worth USD 271,910
Cadence Design SVP Paul Cunningham disposes of 2,000 common shares worth $646,640
PayPal President, Global Markets Suzan Kereere sells USD 253,933 of common shares
